Dr. Seiwert has 17 years of experience in the pharmaceutical industry, focused on drug discovery, preclinical development, and first-in-human clinical studies. Most recently, he served as Senior Vice President of Research and Technical Development at InterMune, where he was also a member of the Executive Committee, until its acquisition by Roche in 2014. In this capacity, he supported all nonclinical aspects of the antifibrotic drug Esbriet® in relation to its approval by the FDA and EMEA. Dr. Seiwert was also a scientific co-founder of Alios Biopharma, which was sold to Johnson & Johnson in that same year. Prior to these roles, he served as Director of Research at Sirna Therapeutics. Dr. Seiwert holds a Ph.D. in Molecular Biophysics and Biochemistry from Yale University School of Medicine.